İstanbul Sağlık ve Teknoloji Üniversitesi Kurumsal Akademik Arşivi
DSpace@İSTÜN, Üniversite mensupları tarafından doğrudan ve dolaylı olarak yayınlanan; kitap, makale, tez, bildiri, rapor, araştırma verisi gibi tüm akademik kaynakları uluslararası standartlarda dijital ortamda depolar, Üniversitenin akademik performansını izlemeye aracılık eder, kaynakları uzun süreli saklar ve telif haklarına uygun olarak Açık Erişime sunar.
Güncel Gönderiler
From awareness to action: Do the food safety attitudes affect sustainable food consumption behaviors in university students?
(Frontiers Media S. A., 2026) Pınarlı Falakacılar, Çağla; Bilginer Diler, Gamzegül; Terzi, Merve
Background: Ensuring food safety and promoting sustainable food consump tion are increasingly important public health priorities, especially among young adults who are forming long-term dietary habits. This study explored how univer sity students’ food safety attitudes relate to their sustainable food consumption behaviors. Methods: This cross-sectional study was conducted with 360 university students between May and September 2024. Validated scales were used to measure food safety attitudes (FSAS) and sustainable food consumption behaviors (SFCBS). Additional data collected included gender and body mass index (BMI). Statistical analyses evaluated differences between groups and correlations among key variables. Results: The findings showed that 83.3% of participants had adequate food safety attitudes. Female students scored significantly higher than males on both the food safety attitude and SFCBS scales, including subdimensions such as caring, assimilating, and shopping/cooking habits (p < 0.05). A moderate positive corre lation was identified between FSAS and SFCBS, particularly for general nutritional behaviors (r = 0.446, p < 0.05). Additionally, positive correlations were found between SFCBS and FSAS subdimensions. Conclusion: Overall, the results indicate that female students exhibit stronger food safety attitudes and sustainable food consumption behaviors, and that fos tering awareness of these practices during university years may contribute to healthier, more environmentally responsible lifestyles in line with global sustain ability goals.
Post-vaccination SARS-CoV-2 infections and antibody responses after BNT162b2 in patients with severe obesity: A retrospective cohort study
(Frontiers Media S. A., 2026) Kara, Zehra; Ak, Tümay; Demir, Ahmet Numan; Akçin, Rüveyda; Dinç, Harika Öykü; Taşkın, Halit Eren; Gareayaghi, Nesrin; Kocazeybek, Bekir; Yumuk, Volkan Demirhan
Aim: The aim of this study was to describe the frequency of post-vaccination SARS-CoV-2 infection and to compare SARS-CoV-2 IgG antibody levels between patients with severe obesity and individuals without obesity after two doses of the BNT162b2 vaccine. Methods: One hundred two consecutive patients with severe obesity seen in the obesity outpatient clinic and 54 individuals without obesity who visited a vaccination outpatient clinic were included in the study. Inactivated Severe Adult Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgG levels of these two groups were measured four weeks after administration of two doses of BNT162b2 vaccine. SARS-CoV-2 infection was defined as a PCR-confirmed infection documented in hospital records during the 12-month follow-up after completion of two-dose BNT162b2 vaccination. PCR testing was performed only when participants presented to the hospital with clinical suspicion of COVID-19 and was not conducted as routine screening. Clinical characteristics, protective measures and contact history were also queried. Results: There was a statistically significant difference in SARS-CoV-2 infection rates after vaccination between the patients with severe obesity (n=28, 27%) and individuals without obesity (n=3, 5%) (p=0.001). In patients with severe obesity, SARS-CoV-2 IgG levels after BNT162b2 vaccination were lower in the group with SARS-CoV-2 infection than in the group without SARS-CoV-2 infection [2697 (1096-8955); 8103 (2208-26903) AUml, respectively] (p=0.008). The antibody levels of those with severe fatigue were lower than those without these complaints [2440 (365-4447); 8955 (2440-16317) AUml, respectively] (p=0.03). A loss of taste or smell was observed in 75% of patients with severe obesity but was not observed in individuals without obesity (p=0.03). In patients with severe obesity, those with taste/smell loss had statistically significantly lower SARS CoV-2 IgG titres than those without severe obesity [2568 (400-4830); 95(2611-16810) AUml, p: 0.02]. Multiple logistic regression analysis revealed a correlation between body mass index (BMI) and having had a SARS-CoV-2 infection after BNT162b2 vaccination (p = 0.028, Exp(B) = 1.072). There was no need for hospitalisation due to SARS-CoV-2 infection and there were no deaths in either group. Conclusion: Patients with severe obesity had higher rates of SARS-CoV-2 infection after BNT162b2 vaccination compared to individuals without obesity. SARS-CoV-2 IgG levels were lower in patients with severe obesity after BNT162b2 vaccination. Based on these findings, given the higher frequency of post-vaccination infections in the patients with severe obesity, timely booster vaccination policies may be particularly important for this population.Severe obesity, SARS-CoV-2, BNT162b2, SARS-CoV-2 IgG, breakthrough infection. Key points: The rate of SARS-CoV-2 infection after vaccination was higher in patients with severe obesity than in individuals without obesity.It has been found that antibody levels are lower in patients with severe fatigue symptoms than in patients without these symptoms.Loss of taste or smell was observed at a high rate (75%) in the group with severe obesity, but not in individuals without obesity.In this study, there were no hospitalisations or deaths after vaccination with BNT162b2 in patients with severe obesity.Body mass index (BMI) has been found to negatively affect the likelihood of contracting SARS-CoV-2 infection after receiving the BNT162b2 vaccine.In our study, we emphasise the importance of vaccination in patients with severe obesity.
An update on fertility preservation from the asian society for fertility preservation
(Wiley, 2026) Turan, Volkan; Faizal Bin Ahmad, Mohd; Di, Wen; Gook, Debra; Kaul, Nalini; Kim, Seok Hyun; Ko, Jennifer; Chau Le, Thi Minh; Lee, Jung Ryeol; Öktem, Özgür
Fertility preservation (FP) is a rapidly expanding field in reproductive medicine with still limited data on outcomes. FP aims to protect the fertility of children, women, and men who face the potential risk of fertility loss for various medical conditions, including but not limited to cancer and its gonadotoxic treatment forms. Therefore, it is crucial to provide evidence-based recommendations to assist health professionals in discussing FP options. Our aim was to provide a guideline for multidiscipli nary medical staff in considering the availability of FP options and to help them decide whether to provide FP. The objective of any FP intervention is to minimize or eliminate primary disease burden and to ensure the maintenance or preserving reproductive health. Therefore, people who are at risk of losing fertility should be evaluated for and counseled about future reproductive risks. Embryo, oocyte, and ovarian tissue cryopreservation are the established FP options in adult females, with ovarian tissue cryopreservation the only option for prepubertal girls. A wide range of variables affect the choice of the FP strategy. These include age and ovarian reserve of women, the time available before the initiation of cancer treatment, puber tal status, and cancer type and stage. In males, sperm cryopreservation is a highly effective method in adolescent and adult males, while testicular tissue cryopreservation, which is experimental, is the only available option for prepubertal males. This review addressed the important clinical questions and provided answers for FP in females, males, and children according to the indications and availability of FP.
Complete healing after umbilical mesenchymal stem cell-derived exosome therapy for a refractory complex anal fistula
(Springer Nature Link, 2026) Arslan, Çiğdem; Erenler, İlknur; Karaöz, Erdal
Complex anal fistulas pose a persistent challenge due to high recurrence and the risk of continence impairment. While sphincter-sparing techniques exist, outcomes are variable in refractory disease. Mesenchymal stromal cell (MSC) therapies show promise but face logistical barriers, prompting interest in acellular exosome-based approaches. We report a 45-year-old woman with a complex anterior anal fistula refractory to multiple surgeries, including two endoanal advancement flaps, complicated by new-onset flatus incontinence. Following the second endoanal advancement flap, the patient's Cleveland Clinic Continence Score (CCIS) was 10, and the Quality of Life in Patients with Anal Fistula Questionnaire (QoLAF-Q) score was 51. A two-stage salvage strategy was undertaken: meticulous curettage and closure of the internal opening, followed by local administration of MSC-derived exosomes at baseline and three weeks. Significant wound reduction was observed, progressing to complete epithelialization within two weeks after the second exosome application. At six months after combined surgical intervention and exosome therapy, CCIS and QoLAF-Q scores improved to 0 and 28, respectively, indicating full restoration of continence and a marked improvement in quality of life. This case suggests that local exosome therapy, used as an adjunct to careful surgical preparation, may support healing and functional recovery in refractory complex anal fistulas. Controlled studies with standardized protocols are warranted to define efficacy, dosing, and durability.
Phenol for pilonidal sinus disease: A nationwide survey of practice patterns and safety gaps among surgeons in Türkiye
(BioMed Central, 2026) Ergüder, Ender; Yahya, Duha; Turan, Ersin; Şimşek, Gürcan; Bulut, Sezer; Arslan, Çiğdem
Background Phenol is widely used as a minimally invasive treatment for pilonidal sinus disease (PSD); however, its clinical application is characterized by substantial heterogeneity in indications, technique, dosing, and safety practices. Despite its routine use in outpatient settings, standardized safety frameworks addressing occupational exposure, environmental controls, and dose documentation are lacking. These gaps may have important implications for both patient outcomes and workplace safety. This nationwide survey aimed to characterize real-world phenol practice patterns among surgeons in Türkiye, with a particular focus on safety infrastructure, exposure control measures, and clinical decision-making. Methods A nationwide, internet-based, cross-sectional survey of surgeons managing PSD in Türkiye (July 8– August 15, 2025), aligned with CHERRIES. The 38-item instrument captured demographics; workload/experience; environmental controls (ventilation), institutional exposure-prevention policies, and personal protective equipment (PPE); patient-side protection strategies; phenol procurement, formulation/concentration, and dosing; treatment planning; and outcomes/perceptions. Descriptive statistics summarized item-level responses. Results A total of 132 surgeons provided responses. 81.1% evaluated more than 30 PSD patients annually, and 48.5% conducted more than 30 phenol procedures per year. Surgeons frequently procured phenol from external pharmacies (36.4%); crystalline phenol predominated (77.3%); 50.8% did not know the concentration (most reported 99.9%); and only 7.6% measured dose per procedure. The majority of surgeons performed 2 to 3 sessions (69.0%) at intervals of 2 to 3 weeks (38.6%). Key safety gaps were identified: only 34.8% reported dedicated ventilation, 53.0% reported none, and 62.1% had no institutional exposure-prevention policy. Routine mask use was reported by 53.8% (primarily surgical masks); additional PPE beyond mask and gloves was used by 22.0% (gowns 51.7%, eye protection 48.3% among those reporting). Patient-side skin protection was common (81.3%). Adverse events in patients were recorded at a rate of 20.5%, with skin burns being the most prevalent, while operator adverse effects occurred at a rate of 5.3%. Despite these gaps, perceived safety was relatively high (patients 83.3%, operators 68.9%), and 89.4% would personally choose phenol if affected. Conclusions Findings support a safety-first national framework specifying permissible formulations/concentrations, mandating dose documentation and skin-protection protocols, and implementing a core safety bundle (effectiveventilation, written exposure-control policies/checklists, and PPE including eye protection). Prospective exposure monitoring with standardized outcomes is warranted.
